DUBLIN--(BUSINESS WIRE)--Sep. 19, 2016--
Alkermes
plc (NASDAQ: ALKS) announced today that it will webcast its Analyst
and Investor Event presentation on Monday, September 26, 2016. The
webcast will begin at 2:00 p.m. EDT (7:00 p.m. BST). At the event,
members of Alkermes’ senior management will provide an overview of
medical, commercial, policy and market perspectives for VIVITROL®
(naltrexone for extended-release injectable suspension).
A live webcast of the event will be available on the Investors section
of the company’s website at www.alkermes.com.
To ensure a timely connection to the webcast, it is recommended that
users register at least 15 minutes prior to the scheduled start. This
webcast will be archived on the Investors section of the company’s
website at www.alkermes.com
for one month following the presentation.
Alkermes plc is a fully integrated, global biopharmaceutical company
developing innovative medicines for the treatment of central nervous
system (CNS) diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates for
chronic diseases that include schizophrenia, depression, addiction and
multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has
an R&D center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more information, please visit Alkermes’ website
at www.alkermes.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006058/en/
Source: Alkermes plc
Alkermes plc
Jennifer Zibuda, +1 781-609-6129
Corporate
Communications
